A targeted program that allows all prescribers to access real-time data and track and compare their own performance with those of others can improve compliance with opioid prescribing guidelines.
Researchers aimed to clarify the role of contextual effect in widely used nonpharmacologic, nonsurgical treatments for knee osteoarthritis by conducting a literature review of knee osteoarthritis trials.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults ≥18 years old.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.
Patients on long-term opioid treatment for chronic pain reported experiencing negative physical side effects, emotional distress, and degraded relationships with their primary care provider.
